Efficacy and safety of incretin co agonists: Transformative advances in cardiometabolic healthcare Effects of GLP 1 (blue arrows), glucagon (red arrows) and GIP (green Download Scientific Diagram Emerging Therapies in Metabolic Health: A Comprehensive Review of GLP1, GIP, and Glucagon Agonists Khan 2026 Journal of Peptide Science Wiley Online Library Beyond a singular focus on GLP 1: why we need a new nomenclature now The Lancet Diabetes & Endocrinology Glucagon like peptide 1 (GLP 1) receptor agonists are incretin analogues that promote glucose mediated insulin release and are used to treat type 2 diabetes mellitus and #obesity. GLP 1 receptor agonists and GLP 1 and glucose dependent insulinotropic Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit